Cervical multilevel intraspinal stem cell therapy: Assessment of surgical risks in gottingen minipigs

Spine

Volumn 36, Issue 3, 2011, Pages

  Raore, Bethwel ^a   Federici, Thais ^a   Taub, Jason ^a   Wu, Michael C ^b   Riley, Jonathan ^a   Franz, Colin K ^a   Kliem, Michele A ^a   Snyder, Brooke ^a   Feldman, Eva L ^c   Johe, Karl ^d   Boulis, Nicholas M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Neurodigitech LLC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d Neuralstem Inc   (United States)

Author keywords

cell therapy; Microinjection; neural stem cells; pigs; spinal cord

Indexed keywords

BUPRENORPHINE; CEFAZOLIN; METHYLPREDNISOLONE; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPSY; CERVICAL SPINAL CORD; CONTROLLED STUDY; EUTHANASIA; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LAMINECTOMY; MORBIDITY; NEURAL STEM CELL TRANSPLANTATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION;

ANIMALS; CELL LINE; CELL SURVIVAL; CERVICAL VERTEBRAE; FEMALE; GRAFT SURVIVAL; HUMANS; INJECTIONS, SPINAL; LAMINECTOMY; MICROINJECTIONS; POSTOPERATIVE COMPLICATIONS; RECOVERY OF FUNCTION; RISK FACTORS; SPINAL CORD; STEM CELL TRANSPLANTATION; SWINE; SWINE, MINIATURE;

EID: 79551553440     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181d77a47     Document Type: Article

References (36)

1. Miller RH. The promise of stem cells for neural repair. Brain Res 2006;1091:258-64.
2. Webber DJ, Minger SL. Therapeutic potential of stem cells in central nervous system regeneration. Curr Opin Investig Drugs 2004;5:714-19.
3. Yu D, Silva GA. Stem cell sources and therapeutic approaches for central nervous system and neural retinal disorders. Neurosurg Focus 2008;24:E11.
4. Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 2005;3:173-81.
5. Huang H, Chen L, Wang H, et al. Safety of fetal olfactory ensheathing cell transplantation in patients with chronic spinal cord injury. A 38-month follow-up with MRI. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2006;20:439-43.
6. Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008;265:78-83.
7. Huang H, Chen L, Wang H, et al. Infl uence of patients' age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J (Engl) 2003;116:1488-91.
8. Feron F, Perry C, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human spinal cord injury. Brain 2005;128:2951-60.
9. Chen L, Huang H, Zhang J, et al. Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2007;21:961-6.
10. Deda H, Inci MC, Kurekci AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009;11:18-25.
11. Bradley JA. Repairing spinal cord injury by cell transplantation. Transplantation 2008;86:769-71.
12. Fehlings MG. Complete cord injury. J Neurosurg Spine 2005;3:171- 2; discussion 172.
13. Blight A, Curt A, Ditunno JF, et al. Position statement on the sale of unproven cellular therapies for spinal cord injury: the international campaign for cures of spinal cord injury paralysis. Spinal Cord 2009;47:713-14.
14. Owens J. Stem-cell treatments for spinal-cord injury may be worth the risk. Nature 2009;458:1101.
15. Gabriel EM, Nashold BS Jr. History of spinal cord stereotaxy. J Neurosurg 1996;85:725-31.
16. Geron Corporation. World's fi rst clinical trial of human embryonic stem cell therapy cleared. Regen Med 2009;4:161.
17. Lonser RR, Gogate N, Morrison PF, et al. Direct convective delivery of macromolecules to the spinal cord. J Neurosurg 1998;89:616-22.
18. Jeffery ND, Smith PM, Lakatos A, et al. Clinical canine spinal cord injury provides an opportunity to examine the issues in translating laboratory techniques into practical therapy. Spinal Cord 2006;44:584-93.
19. Zurita M, Vaquero J, Bonilla C, et al. Functional recovery of chronic paraplegic pigs after autologous transplantation of bone marrow stromal cells. Transplantation 2008;86:845-53.
20. Riley J, Butler J, Park J, et al. Targeted spinal cord therapeutics delivery: stabilized platform and MER guidance validation. Stereotact Funct Neurosurg 2007;86:67-74.
21. Riley J, Federici T, Park J, et al. Cervical spinal cord therapeutic delivery: preclinical safety validation of a stabilized microinjection platform. Neurosurgery 2009;65:754-61.
22. Federici T, Riley J, Park J, et al. Preclinical safety validation of a stabilized viral vector direct injection approach to the cervical spinal cord. Clin Transl Sci 2009;2:165-7.
23. Xu L, Yan J, Chen D, et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 2006;82:865-75.
24. Usvald D, Motlick J, Marsala M. Analysis of dosing regimen and reproducibility of intraspinal grafting of human spinal stem cells in immunosuppressed minipigs. Cell Transplant. In press.
25. Nayak MS, Kim YS, Goldman M, et al. Cellular therapies in motor neuron diseases. Biochim Biophys Acta 2006;1762:1128-38.
26. Lunn JS, Hefferan MP, Marsala M, et al. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors 2009;27:133-40.
27. Sharp J, Keirstead HS. Therapeutic applications of oligodendrocyte precursors derived from human embryonic stem cells. Curr Opin Biotechnol 2007;18:434-40.
28. Lepore AC, Rauck B, Dejea C, et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci 2008;11:1294-301.
29. Mazzini L, Fagioli F, Boccaletti R, et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4: 158-61.
30. Deshpande DM, Kim YS, Martinez T, et al. Recovery from paralysis in adult rats using embryonic stem cells. Ann Neurol 2006;60:32-44.
31. Xu L, Ryugo DK, Pongstaporn T, et al. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol 2009;514:297-309.
32. Cizkova D, Kakinohana O, Kucharova K, et al. Functional recovery in rats with ischemic paraplegia after spinal grafting of human spinal stem cells. Neuroscience 2007;147:546-60.
33. Yan J, Xu L, Welsh AM, et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med 2007;4:e39.
34. Yan J, Xu L, Welsh AM, et al. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells 2006;24:1976-85.
35. Hefferan MP, Kakinohana O, Santucci C, et al. Lumbar transplantation of human spinal stem cells for the treatment of amyotrophic lateral sclerosis. Chicago, IL: Society for Neuroscience; 2009.
36. Marsala M, Usvald D, Vodicka P, et al. Spinal grafting of human spinal neural precursors: a preclinical safety and dosing study in immunosupressed minipig. San Diego, CA: Society for Neuroscience; 2009.